Topic Overview

For decades, biological aging was viewed as an entropic, irreversible decline. However, recent breakthroughs have redefined aging as a plastic, epigenetic process. By utilising partial cellular reprogramming (i.e. the transient expression of Yamanaka transcription factors), researchers have successfully "reset" the epigenetic clock of murine cells, restoring youthful gene expression patterns and functional capacity without inducing pluripotency or teratoma formation (1). Building on seminal work that restored vision in murine models of glaucoma (2), current efforts are targeting blindness, by reversing the age-related transcriptional decline of retinal pigment epithelium and ganglion cells.

The transition from bench-to-bedside has officially commenced. In 2026, the first-in-human clinical trials (NCT07290244) are initiating to evaluate the safety and efficacy of rejuvenation therapies targeting age-related optic nerve conditions, such as open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION). The experimental treatment, named ER-100, uses an adeno-associated viral (AAV) vector to deliver three Yamanaka transcription factors: OCT4, SOX2, and KLF4 (OSK). This treatment strategy marks a paradigm shift from treating individual age-related diseases to targeting the fundamental biology of agiing itself. As we move from bench to bedside, the goal is not just to live longer, but to ensure that our cellular “hardware” retains the functional vitality of youth.

Expert Perspectives

• Prof. George Muschler, MD, Cleveland Clinic (Ohio, USA): “Carefully targeted and crafted safety trials are the critical first step in making safe, effective and accessible iPSC-derived cell therapies available for patients in need.”
• Dr. Laura Batlle-Morera, Tissue Engineering Unit, Center for Genomic Regulation (Barcelona, Spain): “The search for anti-ageing strategies and interventions to ameliorate age-related diseases has recently expanded to include rejuvenation approaches based on partial cellular reprogramming. However, their clinical translation will require a thorough understanding of the underlying mechanisms, as well as comprehensive evaluation of their safety and efficacy before they can be introduced into the clinical practice.”
• Dr. Keisuke Kaji, University of Edinburgh (Scotland, UK): “Unlike the generation of induced pluripotent stem (iPS) cells, which has been reproduced by hundreds of laboratories globally, the rejuvenation of an entire organism or its individual organs via partial reprogramming has been successfully achieved by only a handful of research groups. Across these published studies, there is significant variation in the delivery methods of Yamanaka factors, expression levels, induction durations, targeted organs, criteria for defining "rejuvenation," and proposed molecular mechanisms. The foundational study behind the development of ER-100 demonstrated that targeting the expression of three Yamanaka factors (OSK) specifically to mouse Retinal Ganglion Cells (RGCs) did not merely reverse age-related changes in gene expression; it actively regenerated mechanically damaged optic nerves, a regenerative capacity typically restricted to embryos and neonates, and successfully restored visual function. Given this groundbreaking preclinical efficacy, the scientific community eagerly anticipates the outcomes of the clinical trial (NCT07290244), as well as the formal publication of the non-human primate data that provided the crucial safety and efficacy basis for the FDA's approval.”

Insights Across the Ecosystem

For Patients

• The immediate impact focuses on healthspan (that is, the period of life spent in good health) rather than mere lifespan. Early trials target localised rejuvenation (e.g., vision restoration) to ensure safety before systemic applications are considered.
• Patients should be aware that, except for the genetic mutations, the aging epigenetic signatures present in the cells can be reset.
• Patients may eventually access multi-system disease-agnostic rejuvenation therapies that address the root cause rather than managing isolated symptoms of individual diseases.
• Key hurdles include access, high initial costs, and uncertain long-term safety profile.
  

For Clinicians and Researchers

• Physicians must prepare for a shift from reactive to proactive medicine. The integration of biological age clocks [e.g., Horvath Clock (3)] into routine diagnostics will be required to monitor therapeutic response and calibrate dosing. 
• Researchers and clinicians should closely monitor the risks associated with cellular reprogramming, particularly the possibility of loss of cell identity. If reprogramming proceeds too far, cells may dedifferentiate, behave abnormally, or acquire tumor-forming potential. Although full pluripotency is a powerful tool, inducing it in vivo may carry significant safety concerns. Partial reprogramming is intended to stop before cells lose their original identity resulting in therapeutic benefit while reducing risk.
• Special attention should also be given to the choice of reprogramming factors. Some factors, especially c-MYC, are linked to increased proliferation and cancer risk. For this reason, therapeutic strategies should be designed carefully, for example, by omitting c-MYC and using safer factor combinations such as OSK rather than OSKM.
• Critical scientific roadblocks remai.: First, ensuring safe, precise and tissue-specific delivery with expression at the appropriate dose and duration and reliable switch off system to prevent unintended, prolonged expression in non-target organs. Second, others include controlling cell-to-cell variability as well as avoiding tissue dedifferentiation remain critical. Finally, the safety and control considerations should be adjusted specifically for each delivery system including viral vectors, inducible systems, mRNA, proteins, small molecules, and CRISPR-based approaches. 
  

For Developers and Industry

• Manufacturing scalability remains a significant barrier. Producing high-purity mRNA or viral payloads at the scale required for "longevity" indications requires unprecedented infrastructure and cost-reduction strategies to ensure equitable access.

For Regulators, Payers and Policy Makers

• Value-assessment frameworks must evolve. If a single intervention can delay multiple chronic diseases (e.g. diabetes, dementia, heart disease), the traditional "one drug, one disease" reimbursement model becomes obsolete. Prophylactic rejuvenation will require long-term safety data that exceeds current trial durations.
• Current approval pathways for therapies are built around disease treatment rather than biological process (of aging). Thus regulators will have to establish surrogate endpoints and validate epigenetic biomarkers that can be accepted as legitimate clinical endpoints.
• Due to risk of teratoma formation and cellular dedifferentiation, standard pharmacokinetics must evolve to include precise tissue-containment mechanics and transient expression preventative protocols.
• Policy makers will need to prepare for the societal implications of a significantly extended healthspan which could radically affect healthcare infrastructure costs; moving from late-stage palliative and chronic care to mid-life epigenetic management and maintenance.

Global ViewpointWe are observing a divergence in global policy. While the US and EU maintain strict, indication-specific pathways, emerging hubs in Saudi Arabia (via the Hevolution Foundation) and Singapore are investing billions into "Geroscience," potentially offering faster, albeit more experimental, regulatory sandboxes for longevity research (4).

What to Watch

• Safety Data (Q4 2026): Initial results from Phase 1 safety trials for ocular and dermatological reprogramming.
• LNP Delivery Innovations: New datasets on tissue-specific LNP targeting that could allow for systemic rejuvenation without liver toxicity.
• Cell Press Symposia: Hallmarks of aging (October 4–6, 2026) in Seville (Spain).
• Gradual recognition of "aging-related decline" in formal clinical classification systems, primarily focusing on cognitive and physiological changes associated with growing older.

REFERENCES

• Haoui M, Reddy P, Izpisua Belmonte JC. Anti-aging strategies and <em>ex vivo</em> organ rejuvenation. Cell Stem Cell. 2026;33(1):13-28.
• Lu Y, Brommer B, Tian X, Krishnan A, Meer M, Wang C, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020 Dec;588(7836):124-9. PubMed PMID: 33268865. Pubmed Central PMCID: PMC7752134. Epub 2020/12/04. eng.
• Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018 Jun;19(6):371-84. PubMed PMID: 29643443. Epub 2018/04/13. eng.
• Amalaraj JJP, Island L, Ong JYY, Wang L, Valderas JHM, Dunn M, et al. Towards Precision Geromedicine in Singapore. GeroScience. 2025 Oct;47(5):6399-409. PubMed PMID: 40335817. Pubmed Central PMCID: PMC12634986. Epub 2025/05/08. eng.